MEDIPOST Co., Ltd. (KOSDAQ:078160)
South Korea · Delayed Price · Currency is KRW | Market Cap | 404.15B +16.8% |
| Revenue (ttm) | 73.90B +2.8% |
| Net Income | -79.57B |
| EPS | -2,167.76 |
| Shares Out | 39.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,795 |
| Open | 10,290 |
| Previous Close | 10,400 |
| Day's Range | 9,950 - 10,460 |
| 52-Week Range | 7,250 - 29,100 |
| Beta | 0.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About MEDIPOST
MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co... [Read more]
Financial Performance
In 2025, MEDIPOST's revenue was 73.66 billion, an increase of 4.25% compared to the previous year's 70.66 billion. Losses were -85.40 billion, 36.6% more than in 2024.
Financial StatementsNews
Charles River (CRL) Partners with Medipost for Cell Therapy Advancements
Charles River (CRL) Partners with Medipost for Cell Therapy Advancements
BDA Advises MEDIPOST on Growth Capital Raise
New York, NY December 18, 2025 --(PR.com)-- BDA Partners is pleased to announce that its client MEDIPOST, a leading stem cell therapeutics & cord blood banking biotech company in Korea, has raised g...